X4 Pharmaceuticals

XFOR

Market cap $350M

4.00 USD

-0.04

0.99%

At close Updated Jan 9, 4:00 PM EST

Pre-market

After hours

4.00

0.00

1 day

-0.99%

5 days

2.56%

1 month

9.89%

3 months

16.62%

6 months

140.96%

Year to date

2.83%

1 year

-76.61%

5 years

-98.27%

10 years

-99.84%

About: X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Employees: 143

Healthcare Biotechnology